Skip to main content

Table 2 Expression level of (A) monocyte genes HGF, HGF-R and resistin and (B) serum microRNAs in non-diabetic controls and patients with T2D

From: Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF and miR-574-3p, in monocytes and serum of patients with T2D

  Non-diabetic controls T2D Non-diabetic cont vs. T2D
P value
N Mean SEM N Mean SEM T test
(A) Monocyte genesa
 HGF 27 1.00 0.49 32 1.17 0.62 0.03
 HGF-R 12 1.00 0.14 10 1.34 0.36 0.40
 Resistin 27 1.00 0.43 32 0.47 0.07 0.24
(B) Serum microRNAsb
 miR-122 40 1.00 0.15 56 0.86 0.23 0.64
 miR-138 13 1.00 0.24 22 0.87 0.17 0.66
 miR-146a 40 1.00 0.12 56 0.71 0.06 0.02
 miR-155 40 1.00 0.07 55 0.95 0.07 0.65
 miR-34c-5p 15 1.00 0.11 23 1.00 0.08 0.96
 miR-410 34 1.00 0.12 46 0.92 1.11 0.63
 miR-574-3p 37 1.00 0.13 53 0.69 0.07 0.03
 miR-576-3p 22 1.00 0.16 36 1.43 0.32 0.31
  1. aGroup size, mean and SEM of HGF, HGF-R and resistin of monocytes. To avoid inter-assay variation, gene levels were expressed in fold change compared to non-diabetic controls, the average of the controls in each assay was set to one (1.00). Differences between groups were tested using independent T test. Levels of significance were set at p = 0.05 (two-tailed). The HGF expression was significantly higher in the monocytes of the patients with T2D as compared to the non-diabetic controls (p = 0.03)
  2. bThis table shows group size, mean and SEM of the fold change values of tested serum microRNAs (reference microRNA sync-cel-mir-39) of the patients with T2D as compared to Non-diabetic controls. Differences between groups were tested using independent T test. Levels of significance were set at p = 0.05 (two-tailed). Serum level of miR-146-a (previously reported [18]) and miR-574-3p, was significantly reduced (p = 0.03) in the T2D sera as compared to the non-diabetic controls when controlling for age, gender, BMI and dyslipidemia